IP Verse

Novartis Ag opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Novartis Ag

Patent Number:
EP2784084
Title:
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof
Applicant:
GENENTECH, INC.
Opposition Date:
Jul 24, 2019
Patent Number:
EP2888626
Title:
Contact Lens With A Hydrophilic Layer
Applicant:
OCULAR DYNAMICS, LLC
Opposition Date:
Jan 18, 2019
Patent Number:
EP2794727
Title:
Ionic Silicone Hydrogels
Applicant:
JOHNSON & JOHNSON VISION CARE INC.
Opposition Date:
Oct 24, 2018
Patent Number:
EP2705073
Title:
Macroinitiator Containing Hydrophobic Segment
Applicant:
JOHNSON & JOHNSON VISION CARE INC.
Opposition Date:
Oct 10, 2018
Patent Number:
EP2855545
Title:
Polymers And Nanogel Materials And Methods For Making And Using The Same
Applicant:
JOHNSON & JOHNSON VISION CARE INC.
Opposition Date:
Aug 1, 2018
Patent Number:
EP1623269
Title:
Hydrogel Contact Lenses And Package Systems And Production Methods For Same
Applicant:
COOPERVISION INTERNATIONAL HOLDING COMPANY, LP
Opposition Date:
Feb 9, 2018

Latest patents of Novartis Ag opposed by its competitors

Patent:
EP3124018
Grant Date:
Apr 24, 2024
Title:
Oral Formulations Of Deferasirox
Oppositions:
2
Patent:
EP3023095
Grant Date:
Nov 8, 2023
Title:
Direct Compression Formulation And Process
Oppositions:
3
Patent:
EP3626270
Grant Date:
Oct 11, 2023
Title:
New Use
Oppositions:
16
Patent:
EP3340989
Grant Date:
Aug 16, 2023
Title:
Mdm2 Inhibitors And Combinations Thereof
Oppositions:
1
Patent:
EP3549514
Grant Date:
Aug 16, 2023
Title:
Integrated Oct-Refractometer System For Ocular Biometry
Oppositions:
1
Patent:
EP3864053
Grant Date:
Jul 5, 2023
Title:
Treatment Of Rms By Switching Therapy
Oppositions:
1
Patent:
EP3451898
Grant Date:
Jun 21, 2023
Title:
Overlay Imaging For Registration Of A Patient Eye For Laser Surgery
Oppositions:
1
Patent:
EP2964202
Grant Date:
May 31, 2023
Title:
Oral Formulations Of Deferasirox
Oppositions:
3
Patent:
EP3618875
Grant Date:
Apr 5, 2023
Title:
Combination Therapy
Oppositions:
1
Patent:
EP3858405
Grant Date:
Apr 5, 2023
Title:
Syringe
Oppositions:
2

Competitors of Novartis Ag

STADA ARZNEIMITTEL AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

GENERICS [UK] LIMITED

Want to track Novartis Ag?

Feel free to send us a message here and we will get back to you